News Medical

PDX engraftment predicts high recurrence and poor survival in triple-negative breast cancer

Patient-derived xenografts (PDX) may accurately predict early recurrence and survival outcomes in triple negative breast cancer (TNBC), offering a potential tool for tailoring treatment strategies to ...
Yahoo

First person in the world to get the breast cancer vaccine says it's changed her life. Here's how it works.

Jennifer Davis is the first person to receive the breast cancer vaccine as part of a clinical trial. (Photo illustration: Yahoo News; photos: Getty Images) Finding a cure for cancer has been the holy ...

How to identify and treat triple-negative breast cancer — a rare but aggressive form of cancer

Triple-negative breast cancer does not respond to targeted breast cancer treatments, which limits treatment to primarily chemotherapy for now.
Los Angeles Times

Triple-Negative Breast Cancer (TNBC): Understanding Diagnosis and Treatment

Triple Negative Breast Cancer (TNBC) is one of the most aggresive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...
Monthly Prescribing Reference

Multigene Signature Can Help Tailor Chemo for Operable Triple-Negative Breast Cancer

Improved 3-year disease-free and recurrence-free survival seen with intensive chemotherapy regimen. HealthDay News — For patients with operative triple-negative breast cancer, a multigene signature ...
Cure Today

Low ctDNA Levels May Show Longer Recurrence-Free Interval in Breast Cancer

The ZEST trial, a phase 3 study on MRD-guided therapy in breast cancer, was terminated early due to low randomization rates. ctDNA was most frequently detected within six months post-treatment, ...
Medscape

Debate Over? Data Support Adjuvant Carboplatin in Early TNBC

Adjuvant carboplatin added to standard anthracycline/taxane chemotherapy significantly improves outcomes in early ...
EurekAlert!

Vaccine shows promise against aggressive breast cancer

A small clinical trial conducted at WashU Medicine shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of ...
KTLA

A novel therapy eradicates triple negative breast cancer recurrence in preclinical models

From left to right, Dr. Fernando Lecanda, Dr. Karmele Valencia, and Dr. Rafael Martínez Monge, from the Adhesion and Metastasis group at Cima, with Dr. Borja Ruiz-Fernández de Córdoba, also author of ...
Business Wire

Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced it has partnered with the Academic Breast Cancer Consortium (ABRCC) and Criterium to carry out a prospective clinical ...
Morningstar

Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect® molecular residual disease (MRD) ...